Good for RBC shareholders. Not so good for TEN shareholders. Especially at current prices of each.
Another step on the long tortuous road to a value event for RBC.
Management attention can now focus on ArborGen and the consortium has some interesting possibilities.
Although not a smash hit, from Rubicon's perspective I think it is quite a clever deal.
I think it is an endorsement of the potential and intention to revalue RBC.